8:00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

Progressing Early Discovery Through to Pre-Clinical: Emerging Research & Optimised Viruses

9:00 am The Cell based Oncolytic Virus Therapy for Cancer: Bench to Bedside Translation

  • Khalid Shah Vice Chair of Research , Brigham And Women’s Hospital


• Creating cellular oncolytic virus platform
• Gene editing and engineering of stem cells for combined oncolytic virus and immunomodulatory delivery
• Assessing the efficacy in clinically relevant mouse tumor models tumor models

9:30 am Using Codon Pair Deoptimization as a Novel Engineering Platform for Immunotherapeutic Viruses


• Codon pair deoptimization can be used to engineer multiple RNA viruses – introduction to the SAVE platform and its application in different disease areas
• Intratumoral treatment of TNBC with CodaLytic shows anti-tumor efficacy and immune modulation in preclinical models of cancer
• Overview of clinical activities to establish safety of CodaLytic in patients

10:00 am Synthetic Oncolytic Virus Therapy for Repeat Systemic Treatment of Cancer


• Therapeutic efficacy of systemic oncolytic virus therapies is curtailed by the rapid emergence of neutralizing antibodies that limit exposure upon repeated dosing
• Synthetic RNA viruses, which consists of a replication competent viral genome encapsulated within a lipid nanoparticle, are designed to enable repeat intravenous dosing leading to efficient viral genome delivery, replication and oncolysis in tumors
• Systemically administered synthetic RNA viruses are highly efficacious even in presence of circulating virus-specific neutralizing antibodies

10:30 am Morning Break & Structured Networking

11:00 am The Design of Oncolytic Viral Therapies for Intravenous Delivery


• Next generation OV therapies will ideally be delivered intravenously
• Modifications of the viral backbone can increase systemic delivery
• Addition of therapeutic transgene combinations can create potent systemic therapies

11:30 am Optimization of a Novel HSV Virus to Circumvent Neutralizing Antibodies

  • Xiaotong Song Assistant Professor, Center for Cell and Gene Therapy , Baylor College of Medicine


• Addition of novel cytokine transgenes to enhance anti-cancer effects
• Identification and mutation of Ab-binding epitope to enhance virus longevity

12:00 pm Lunch Break

1:15 pm Structured Networking

Insights from Within the Clinic: Demonstrating the New Generation of Oncolytic Viruses

1:50 pm Oncolytic Viruses: The Landscape and the Future


• Understanding the current preclinical and clinical view of the oncolytic virus space
• Key trends emerging in the space including combinations with other targeted modalities, transgene/virus family utilization, and novel approaches/technologies, and so on
• A glimpse into the future for OVs in 2021 and beyond

2:20 pm Improving Oncolytic HSV1 for Glioblastoma Therapy

  • Antonio Chiocca Neurosurgeon-in- Chief and Chairman, Department of Neurosurgery, Brigham & Women’s Hospital


• Learn what clinical trials of oncolytic virotherapy for GBM are teaching us
• Description of different avenues to improve efficacy
• Understanding the limits of mouse models to improve clinical design

2:50 pm Rational Design of the HSV-1 Oncolytic Virus for Biomarker-Based Tumor Targeting


• Virogin’s oHSV-1 backbone is uniquely engineered to enhance tumorspecific replication and transgene expression via Transcriptional and Translational Dual Regulation (TTDR), thereby improving efficacy without compromising safety
• We select payload combinations based on the synergy to create a favorable anti-tumor microenvironment and achieve systemic (abscopal) effects
• The rational design of our OVs allows for biomarker-based patient selection with a purpose to develop next generation precision virotherapy products

3:20 pm Combination of multiple cytokines armed oncolytic HSV virus in the treatment of metastatic Tumor

  • Hideki Kasuya Professor, Cancer Immune Therapy, Nagoya University


• The character and potential of oncolytic HSV virus, Canerpaturev (C-REV)
• Clinical trial in Japan and US against melanoma and pancreatic cancer using C-REV
• New generation of C-REV, multiple cytokines armed virus and combination with immunotherapy in the treatment of metastatic Tumor

3:50 pm Afternoon Break

Pediatric Oncolytic Virotherapy: Translating Knowledge to an Underserved Patient Population

4:30 pm Review of Clinical Pediatric Oncolytic Virotherapy, Current Role in Pediatric Oncology and Future Goals

  • Keri Streby Assistant Professor Pediatric Oncology , Nationwide Children’s Hospital


• Understand the latest clinical advancements within the field of pediatric oncolytic virotherapy
• Get to grips with how we can better advance therapies for paediatrics in a safe and efficacious way

5:00 pm A Success Story: Oncolytic Virotherapy in Pediatric Gliomas

  • Gregory Friedman Associate Professor, Division of Pediatric Hematology-Oncology , The University of Alabama at Birmingham


• Advancements in engineered HSV for the treatment if glioblastoma in paediatrics
• Determining mechanisms of therapeutic resistance by exploring the role of tumor genotype, phenotype, and microenvironment; and cellular defense mechanisms so that newer viruses, novel combinations, and unique routes of virus delivery may be developed to circumvent resistance mechanisms

5:30 pm Panel Discussion – Future Perspectives in Using Oncolytic Viruses in Pediatrics

  • Keri Streby Assistant Professor Pediatric Oncology , Nationwide Children’s Hospital
  • Gregory Friedman Associate Professor, Division of Pediatric Hematology-Oncology , The University of Alabama at Birmingham


• Which promising combination therapies showing success in adult trials could we look to apply to
pediatric oncolytic virotherapy?
• What efforts can be done to overcome the challenge of a limited number of immune competent models
available for study, so that the pre-clinical evaluation of OVs required for the subsequent translation to the clinic can be enhanced?
• What fundamental steps are paramount within the remit of pediatric OV which must be taken to
advance the field?

6:00 pm End of Day One